MANNKIND - 2013 endlich zum Überflieger?
Seite 74 von 77 Neuester Beitrag: 24.02.22 17:33 | ||||
Eröffnet am: | 14.02.13 23:07 | von: Oki-Wan 2.0 | Anzahl Beiträge: | 2.92 |
Neuester Beitrag: | 24.02.22 17:33 | von: Vassago | Leser gesamt: | 442.150 |
Forum: | Hot-Stocks | Leser heute: | 67 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 71 | 72 | 73 | | 75 | 76 | 77 > |
meine persönliche Meinung
Das Geld geht aus, die Verschreibungszahlen sind noch immer kaum Erwähnenswert....
* Damit meine ich das Beste Mahlzeit Insulin auf dem Markt, in vielen Studien wurde dies bereits bewiesen. Trotz aller GoodNews in den letzen Monaten verändert sich nichts an der Lage von MNKD
auch ob diese Partnerschaft mit dem Indischen Pharmaunternehmen mal was wird? Kann gerade wieder so ein Rohrkrepierer werden wie dazumals mit Sanofi....
jaa schau dir doch das drum herum an. was kannst du da noch positiv sehn?
Habe nur mal so hier reingeschaut und bin doch etwas verblüfft.
1. Mal ganz ehrlich, wie kommen hier einige User darauf, dass Afrezza das beste Mahlzeiten-Insulin sein soll?
2. Auch die Theorie, dass Sanofi das Produkt absichtlich an die Wand gefahren hat, ist doch völliger Unfug.
Zu 1.
Afrezza ist schnell, ja! Aber das war´s dann auch schon.
Aufgrund seiner Schwankungsbreite (4E Afrezza wirken so wie 1-3E injiziertes Insulin) und den Einschränkungen, die beim Einsatz zu berücksichtigen sind, ist es völlig unbrauchbar im Alltag.
Für Typ-1-Diabetiker ist eine so enorme Schwankungsbreite eines Insulins völlig inakzeptabel.
Mancher reagiert bereits auf 1/2 Einheiten!
Also, wie sollte das im Alltag funktionieren? Völlige illusorisch.
Hinzu kommt noch der allgemeine Trend zu Pumpem, die immer besser werden.
Für Typ-1er ist ein Closed-Loop oft ein Segen.
Hierfür benötige ich aber flüssiges Insulin und kein Pulver!
Für Typ-2er, die ja doch meißt noch ältere Patienten sind (wobei auch die 2er immer jünger werden) ist der Applikator doch etwas zu "fummelig".
Schaut euch ältere Typ-2er an.
Hinzu kommt, dass Typ-2-Diabetiker nicht primär mit Mahlzeiten-Insulin behandelt werde.
Aber der Markt im Bereich des Typ-2 ist um Längen größer.
Zu 2.
Man kann sicher davon ausgehen, dass Sanofi das Maximum aus Afrezza gepresst hätte, wenn der Markt es hergeben würde! Ganz sicher.
Sanofi agiert hier stets sehr gut.
Zudem müsste Sanofi eher ein Intersse haben, andere Langzeitinsuline vom Markt zu halten, da dies das Butter-und-Brot-Geschäft im Bereich Insuline (Lantus, Toujeo) ist.
Also, warum derart viel Energie in das Verdrängen eines neuen Mahlzeiteninsulin stecken, was mir als Unternehmen nicht sonderlich weh tut, da mein Fokus nicht auf diesem Marktsegment liegt?
Wenn Unternehmen daran Interesse gehabt haben sollten, dann wohl eher Lilly Und Novo Nordisk, da beide mit schnelleren, injizierbaren Mahlzeiteninsulinen im Markt aktiv sind/werden.
Diese Verschwörungstheorien scheinen mir nur der Versuch zu sein, sich nicht eingestehen zu müssen, dass es für Afrezza objektiv keinen ausreichenden Markt gibt.
Nur so zur Info, falls jetzt wieder der ein oder andere daher kommt und mir Ahnungslosigkeit unterstellen möchte.
Ich bin seit 1993 in der Pharmaindustrie/Vertrieb tätig und davon seit 14 Jahren bei einem großen Insulinproduzenten.
Daher traue ich mir durchaus zu, den Markt einigermaßen einschätzen zu können.
Aber! Auch das schützt mich nicht vor Fehleinschätzungen, dessen bin ich mir bewusst.
Dennoch bin ich mir bei Afrezza sehr sicher, dass es tot ist, wie ja auch der Kurs seit Jahren beweist.
United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments
Research agreement for additional products for additional $10 million
SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.
Under the agreement, United Therapeutics will be responsible for global development, regulatory and commercial activities. MannKind will manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Danbury, Connecticut. Long-term commercial supplies will be manufactured by United Therapeutics.
Under the terms of the agreement, MannKind Corporation will receive an upfront payment of $45 million and potential milestone payments of up to $50 million, dependent upon the achievement of specific development targets. MannKind will also be entitled to receive low double-digit royalties on net sales of the product. In addition, MannKind granted United Therapeutics an option to expand the license to include other active ingredients for the treatment of pulmonary hypertension. Each optioned product would be subject to the payment to MannKind of up to $40 million in additional option exercise and development milestone payments as well as a low double-digit royalty on net sales of any such product.
The effectiveness of the licensing and collaboration agreement is conditioned on expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
The parties also entered into a research agreement for the conduct of research by MannKind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement. MannKind will receive an immediate payment of $10 million in consideration for its performance under the research agreement.
“We are excited to partner with United Therapeutics, a company that shares our passionate focus on changing patients’ lives,” stated Michael Castagna, Pharm.D., Chief Executive Officer of MannKind. “We are pleased with this new opportunity to demonstrate the value of our drug and device combination platform for delivering therapeutic products. We believe this collaboration will have the potential to significantly improve the lives of people living with pulmonary arterial hypertension.”
“On the very same day 21 years ago, we enabled the development of treprostinil into a practical treatment thanks to an invention of the late Al Mann – the discrete, ambulatory, programmable, parenteral infusion pump called the MiniMed 407c,” said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. “By marrying our molecule and MiniMed’s device, Remodulin® was born. As we now move into the second generation of United Therapeutics products, we are proud to once again team with Al Mann’s brilliance, this time with his Dreamboat®, Bluhale® and Cricket® devices for inhalation. I believe these revolutionary new inhalation devices will accomplish for Tyvaso® what our recently-approved Implantable System for Remodulin, pending RemUnity™ system and recently-acquired Trevyent® product represent for Remodulin – a further step toward a next generation of treprostinil drug-device systems that enhance options for patients, their families and their prescribers.”
Conference Call
MannKind will host a conference call today at 4:00 p.m. Eastern Time. To listen to the conference call webcast live via the Internet, visit the Company's website at www.mannkindcorp.com and click on the link in the Webcasts section of News & Events. To participate in the live call by telephone, please dial (800) 289-0438 toll-free or (323) 794-2423 toll/international and use the conference passcode: 6006518.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 toll-free or (412) 317-6671 toll/international and use the replay passcode: 6006518. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
About United Therapeutics
United Therapeutics is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]
United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery
Share
Share
Tweet
Save
Order Reprints
Martine Rothblatt, CEO of United Therapeutics, has struck another big deal to commercialize a new delivery device for a pulmonary arterial hypertension drug.
Enlarge
Martine Rothblatt, CEO of United Therapeutics, has struck another big deal to commercialize a new delivery device for a pulmonary arterial hypertension drug.
Lenzy Ruffin
In This Article
Alfred Mann Person
Health Care Industry
MannKind Corp. Company
Manufacturing Industry
Martine Rothblatt Person
United Therapeutics Company
By Michael Neibauer – Associate Editor, Washington Business Journal
46 minutes ago
Silver Spring-based United Therapeutics Corp. announced Tuesday that it will pay a California company $95 million to partner in the development, manufacture and commercialization of a new treatment for pulmonary arterial hypertension.
Under the deal with MannKind Corp. (NASDAQ: MNKD), United Therapeutics (NASDAQ: UTHR) will be responsible for global development, regulatory and commercial activities for the dry power formulation and inhalation delivery of treprostinil, the active ingredient in United Therapeutics' flagship product Remodulin. The system is currently in the clinical trials stage.
Westlake Village, California-based MannKind will manufacture clinical supplies and initial commercial supplies out of its Danbury, Connecticut plant, while United Therapeutics will manufacture long-term commercial supplies of the product.
The deal provides for a $45 million upfront payment to Mannkind and potential payments of another $50 million, dependent on certain development targets. Mannkind will also be eligible for “low double-digit royalties” on net sales of the product, per a release.
United Therapeutics has a long history with treprostinil and MannKind. Exactly 21 years ago, UT CEO Martine Rothblatt said in a statement, the Maryland company combined one of its creations with a parenteral infusion pump called MiniMed 407c, invented by Alfred Mann, to create Remodulin.
Rothblatt said the new inhalation devices will be "revolutionary."
In late July, United Therapeutics received Federal Drug Administration approval for an implantable pump for Remodulin. The drug, perhaps soon-to-be-available as a generic, generated sales of $286.3 million in the first six months of the year for United Therapeutics.
The deal extends beyond treprostinil. MannKind granted United Therapeutics an option to expand the license to include other active ingredients for the treatment of pulmonary hypertension — subject to an additional $40 million payment per license. And the California company will get another $10 million immediately to conduct research “on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.”
Trending
Commercial Real Estate
Behind the deal: How Virginia landed the $3B Micron expansion
Micron President and CEO Sanjay Mehrotra at an announcement for his company's $3 billion, 1,100-job expansion in Manassas.
Commercial Real Estate
Micron to invest $3B in Manassas operation, add 1,100 jobs
Pictured here is Micron Technology's facility in Manassas, where the company employs 1,500 workers.
Home of the Day
Gorgeous Eastern Shore Estate
Sponsored Listing
Könnte bis 3,5-4$ laufen, wohlgemerkt könnte!
Premarket wird den Weg zeigen, natürlich eine gute News, aber die Finanzlage bleibt prekär!